🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A huge milestone in #kidneycancer therapy! Hats off to Toni Choueiri, MD Tom Powles & team for leading this pivotal study - & many thanks to the thousands of patients who have participated in adjuvant trials (this & so many others) over the past several decades. Without their courage

The 7th National Hellenic oncology Congress ΕΟΠΕ just began , all of us and our special distinguished guest expert and amazing person Charu Aggarwal, MD, MPH, FASCO are looking forward to welcome all of you!! #some #lcsm Marita Lykka MD ESMO - Eur. Oncology IASLC ASCO OncoAlert

Terrific 7th Annual Hellenic Society of Oncology meeting and a wonderful opportunity to connect with colleagues Giannis Mountzios Helena Linardou Marita Lykka MD - humbled to have contributed to keynote and mentoring sessions and a chance to visit this beautiful country! 🇬🇷 ESMO - Eur. Oncology

Updated clear cell renal cancer guidlines ESMO - Eur. Oncology.Ipi/nivo now has additional weak support in IMDC good risk (I,C). Belzutifan gets strong support in 3rd line (I,B) but less strong 2nd line (VEGF TKI preferred).1st line PD1/VEGF unchanged Annals of Oncology ow.ly/nZA050RP77l

Join us for fantastic meeting in Vienna on practical data applications in GU cancers! Giannis Mountzios Marinos Tsiatas Marita Lykka MD MikaLion Ζenia Saridaki Enrique Grande Daniel Castellano Bernadett Szabados Uromigos Ursula Vogl Badrinath Konety, MD, MBA Vadim Koshkin MD silke gillessen OncoAlert Myrto K. Moutafi ANASTASIOS KYRIAZOGLOU

What is HER2 « ultralow » breast cancer, and why should you care? A thread:

Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute

NIAGARA. Chemo +Durva is a NEW SOC in HIGH RISK PERIOP Muscle-Invasive Bladder Cancer #ESMO24. Tom Powles does it again! Concomitant NEJM paper!

📰 If you found these facts of interest, stay tuned for an upcoming review article led by Raffaele Colombo & myself, which will retrace the lessons learned over the last 40 years of development of ADCs Also, make sure to attend the ADC session of #ENA24! event.eortc.org/ena2024 11/11

Super relevant data NEJM Results after Four Years of Screening for Prostate Cancer with PSA and MRI Key findings: Four-year results show MRI-targeted prostate cancer screening reduces overdiagnosis by 57%, cuts biopsies by up to 74%, and maintains effectiveness in detecting

DUARTtrial ph2 - interesting results in a very specific patient subgroup more and more common in our clinical practice. Frailty and advanced age should not be an obstacle in providing high quality and evidenced based treatment. #ESMOImmuno24

Exciting 177Lu-PSMA-617 has been approved by the FDA for use prior to chemotherapy based on the PSMAfore results. Perfect timing, during day 1 of the PSMA and Beyond Conference! bit.ly/42lfdlz

The FDA approved perioperative duvalumab with neoadjuvant chemo for muscle invasive bladder cancer today. It’s the only perioperative immune therapy trial with significant OS (0.75). Surgical safety was maintained. NCCN approval recently too #GUtrends25 fda.gov/drugs/resource…

#ELCC2025 Next Generation ADCs - Impressive talk by Giannis Mountzios ,regarding future treatment evolution in patients with oncogenic addicted NSCLC

BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

Join our friends & 🚨Faculty Brian Rini, MD 🇺🇸and Tom Powles 🇬🇧 (The Uromigos ) as they discuss: ADC 💊#BladderCancer PART 2⃣ New ADCs in bladder cancer THIS IS PART TWO IN A TWO PART SERIES Sumanta K. Pal, MD, FASCO Cristiane D Bergerot Daniel Heng Andrea Apolo, M.D. Toni Choueiri, MD Petros Grivas

ESMO 2024 Quick Take Insights: Prostate Cancer - #ARANOTE: Darolutamide + ADT shows significant rPFS benefits in mHSPC, offering a new treatment without docetaxel. - #PEACE3Study: Radium-223 + enzalutamide in mCRPC enhances rPFS & OS when used with bone protection in patients

🔥🚨OncoAlert Hot Off the Press #BigNews Press Release by Amgen 🧪🔬🧬 #DeLLphi304 trial of #IMDELLTRA (#TARLATAMAB) vs #Chemotherapy in 2nd line Tx for patients with #SmallCell #LungCancer shows: ✅Statistically Significant & Clinically Meaningful Improvement in #OverallSurvival

⚡️ In European Urology - Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group #BladderCancer Ashish M. Kamat, MD, MBBS Shilpa Gupta Prof Ananya💙 @achoud72.bsky.social Dr. Bishoy M. Faltas Kent Mouw Andrea Necchi Petros Grivas Roger Li

Final MAGNITUDE 📢 In mCRPC with BRCA mutations: Niraparib to Abiraterone = ⬇️ progression risk by 47% ⏳ rPFS: 19.5 vs 10.9 months 🧬 No benefit in non-HRR pts ✅ Confirmed the biomarker-driven benefit! European Urology Oncology OncoAlert Advanced Prostate Cancer Consensus Conference Elena Castro AttardLab